Investigators at Queen’s University Belfast have discovered a novel experimental treatment for chronic lung diseases that could improve the lives of people with cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). As reported in MDLinx, the researchers have identified symptoms associated with both diseases can be alleviated through inhibiting the activity of an enzyme found in the lungs. Building on previous study by Queen’s University Belfast that found that high levels of a particular enzyme, cathepsin S, in the lungs of children with CF were associated with increased inflammation and lung damage. The CF research, published in the European Respiratory Journal, brought together experts from Queen’s University Belfast, Charité Universitätsmedizin Berlin, INSERM Paris, and Virobay Inc. USA.
Professor Cliff Taggart from the Wellcome-Wolfson Centre for Experimental Medicine at Queen’s University